How Has the Corneal Endothelial Dystrophy Market Size Evolved in Recent Years?
The corneal endothelial dystrophy market has seen considerable growth due to a variety of factors.
• In the past few years, the market for corneal endothelial dystrophy has seen substantial growth. This market, valued at $170.96 billion in 2024, is predicted to increase to $185.38 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.4%.
This considerable growth throughout the historic period can be linked to factors such as increased healthcare spending, a heightened occurrence of corneal endothelial dystrophy, an aging population base, a rising incidence of eye-related ailments, and a widespread increase in corneal disorder cases.
What Is The Forecast For The Corneal Endothelial Dystrophy Market Size?
The corneal endothelial dystrophy market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for robust expansion in the corneal endothelial dystrophy market over the next few years, with an expected market size of $252.88 billion by 2029, showing a compound annual growth rate (CAGR) of 8.1%.
This anticipated growth during the forecast period is primarily due to factors such as heightened prevalence of corneal blindness in emerging economies, increased public awareness about eye care, a growing need for corneal transplantation, improved healthcare infrastructure, and a rise in chronic diseases. The forecast period will also be characterized by key trends such as progress in regenerative therapies, advancements in medical technology, development in diagnostic methodologies, technological upgrades in ophthalmic lasers, and cutting-edge techniques.
What Are The Leading Drivers Of Growth In The Corneal Endothelial Dystrophy Market?
The escalating need for corneal transplants is predicted to fuel the expansion of the corneal endothelial dystrophy market in the future. Corneal transplant involves the surgical replacement of a diseased or damaged cornea with a healthy one from a donor, to improve vision and overall eye health. The surge in the demand for corneal transplants can be attributed to the increasing occurrence of corneal diseases, advancements in surgical procedures, and enhanced rates of organ donation. Corneal endothelial dystrophy can be managed through corneal transplant surgery, wherein the impaired endothelium is replaced by healthy donor tissue, resulting in restored corneal clarity, reduced edema, and improved eyesight. For example, the Eye Bank Association of America, a US-based transplant group, reported an increase of 2.7% in domestic keratoplasty (a type of corneal transplant) procedures, from 49,597 in 2022 to 50,925 in 2023. Consequently, the surging requirement for corneal transplants is influencing the growth of the corneal endothelial dystrophy market.
How Is The Global Corneal Endothelial Dystrophy Market Divided Into Key Segments?
The corneal endothelial dystrophy market covered in this report is segmented –
1) By Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps
2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy
3) By Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Phototherapeutic Keratectomy: Excimer Laser Therapy, Corneal Reshaping
2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant, Cryopreserved Amniotic Membrane Transplant
3) By Anterior Stromal Puncture: Manual Technique, Laser-Assisted Technique
4) By Conjunctival Flaps: Partial Flap Technique, Full Flap Technique
Pre-Book The Corneal Endothelial Dystrophy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Corneal Endothelial Dystrophy Market?
In the corneal endothelial dystrophy market, prominent companies are concentrating on devising novel therapies such as allogeneic cell therapy to provide groundbreaking, minimal-invasive treatment choices, which heighten patient results while addressing unmet medical needs. Allogeneic cell therapy involves utilizing cells from a same-species donor yet genetically different to treat a recipient. For example, in September 2024, the U.S based Aurion Biotech Inc., a clinical-stage biotech company, introduced Vyznova (neltependocel) in Japan. This drug is intended to treat bullous keratopathy, a corneal endothelial disease. Running parallel with Aurion Biotech's approach to treating bullous keratopathy which damages corneal endothelial cells resulting in vision impairment, Vyznova became the first approved cell therapy for corneal endothelial disease in Japan. The cell therapy uses lab-cultivated corneal endothelial cells, permitting up to 1,000 doses to be prepared from a single donor. Positioning as a less invasive substitute to corneal transplantations, Vyznova's breakthrough treatment helps confront the deficiency of corneal donors while offering a renewed perspective to those afflicted with corneal diseases.
Who Are the Key Players In The Corneal Endothelial Dystrophy Market?
Major companies operating in the corneal endothelial dystrophy market are:
• F. Hoffmann-La Roche AG
• Abbvie (Allergan plc)
• Teva Pharmaceutical Industries Ltd
• Fujifilm Holdings Corporation
• Alcon Inc.
• Bausch Health+Lomb
• Santen Pharmaceutical Co.. Ltd.
• AGC Biologics Inc
• Lumenis Ltd
• Aurion Biotech Inc
• Carl Zeiss Meditec AG
• Keeler Limited
• Kowa Company Ltd.
• ProQR Therapeutics N.V.
• Cellusion Inc.
• OptoTech GmbH
• ActualEyes Inc.
• Arctic Vision Inc.
• Aurion Biotech LLC
• Emmecell S.R.L
What Are The Regional Insights Into The Corneal Endothelial Dystrophy Market?
North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
